Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 1215Neoplasms 1024Carcinoma, Non-Small-Cell Lung 747Prostatic Neoplasms 687Colorectal Neoplasms 590Lung Neoplasms 572Pancreatic Neoplasms 394Leukemia, Myeloid, Acute 394Neoplasm Metastasis 387Ovarian Neoplasms 370Multiple Myeloma 369Stomach Neoplasms 316Carcinoma, Hepatocellular 301Melanoma 281Brain Neoplasms 277Recurrence 273Squamous Cell Carcinoma of Head and Neck 267Head and Neck Neoplasms 237Endometrial Neoplasms 234Glioblastoma 233Triple Negative Breast Neoplasms 228Uterine Cervical Neoplasms 221Precursor Cell Lymphoblastic Leukemia-Lymphoma 221Lymphoma 221Sarcoma 201Hematologic Neoplasms 199Urinary Bladder Neoplasms 196Esophageal Neoplasms 190Carcinoma, Renal Cell 187Lymphoma, Non-Hodgkin 175

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Gastric Adenocarcinoma × 1 year × Clear all
NCT05041153 2026-01-12

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Recruiting
15 enrolled
Gastrointestinal

Advanced Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡